Avanos Medical Financial Statements (AVNS)
|
|
Report date
|
|
|
19.02.2021 |
23.02.2022 |
31.12.2022 |
21.02.2023 |
21.02.2024 |
|
30.10.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
714.8 |
744.6 |
820.0 |
820.0 |
673.3 |
|
681.5 |
Operating Income, bln rub |
|
|
-46.1 |
8.90 |
74.0 |
74.0 |
4.20 |
|
57.7 |
EBITDA, bln rub |
? |
|
-2.00 |
8.90 |
122.9 |
77.8 |
53.2 |
|
96.6 |
Net profit, bln rub |
? |
|
-27.2 |
6.30 |
50.5 |
50.5 |
-61.8 |
|
15.7 |
|
OCF, bln rub |
? |
|
-2.50 |
87.3 |
90.9 |
90.9 |
32.4 |
|
55.5 |
CAPEX, bln rub |
? |
|
20.2 |
21.0 |
19.3 |
19.3 |
17.8 |
|
18.9 |
FCF, bln rub |
? |
|
-22.7 |
66.3 |
71.6 |
71.6 |
14.6 |
|
36.6 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
419.4 |
355.4 |
376.0 |
376.0 |
375.5 |
|
323.0 |
Cost of production, bln rub |
|
|
341.5 |
380.3 |
370.0 |
370.0 |
293.6 |
|
300.8 |
R&D, bln rub |
|
|
34.9 |
32.3 |
30.6 |
30.6 |
27.2 |
|
27.3 |
Interest expenses, bln rub |
|
|
15.6 |
3.30 |
10.00 |
10.00 |
15.0 |
|
12.7 |
|
Assets, bln rub |
|
|
1 673 |
1 595 |
1 787 |
1 787 |
1 692 |
|
1 656 |
Net Assets, bln rub |
? |
|
1 257 |
1 264 |
1 291 |
1 291 |
1 236 |
|
1 230 |
Debt, bln rub |
|
|
248.8 |
187.5 |
280.0 |
280.0 |
209.1 |
|
202.2 |
Cash, bln rub |
|
|
111.5 |
118.5 |
127.7 |
127.7 |
87.7 |
|
89.0 |
Net debt, bln rub |
|
|
137.3 |
69.0 |
152.3 |
152.3 |
121.4 |
|
113.2 |
|
Ordinary share price, rub |
|
|
45.9 |
34.7 |
27.1 |
27.1 |
22.4 |
|
21.5 |
Number of ordinary shares, mln |
|
|
47.8 |
48.1 |
46.9 |
46.9 |
46.6 |
|
46.0 |
|
Market cap, bln rub |
|
|
2 193 |
1 668 |
1 269 |
1 269 |
1 045 |
|
991 |
EV, bln rub |
? |
|
2 330 |
1 737 |
1 421 |
1 421 |
1 167 |
|
1 104 |
Book value, bln rub |
|
|
296 |
321 |
221 |
221 |
201 |
|
215 |
|
EPS, rub |
? |
|
-0.57 |
0.13 |
1.08 |
1.08 |
-1.33 |
|
0.34 |
FCF/share, rub |
|
|
-0.47 |
1.38 |
1.53 |
1.53 |
0.31 |
|
0.80 |
BV/share, rub |
|
|
6.20 |
6.68 |
4.71 |
4.71 |
4.31 |
|
4.66 |
|
EBITDA margin, % |
? |
|
-0.28% |
1.20% |
15.0% |
9.49% |
7.90% |
|
14.2% |
Net margin, % |
? |
|
-3.81% |
0.85% |
6.16% |
6.16% |
-9.18% |
|
2.30% |
FCF yield, % |
? |
|
-1.04% |
3.98% |
5.64% |
5.64% |
1.40% |
|
3.69% |
ROE, % |
? |
|
-2.16% |
0.50% |
3.91% |
3.91% |
-5.00% |
|
1.28% |
ROA, % |
? |
|
-1.63% |
0.40% |
2.83% |
2.83% |
-3.65% |
|
0.95% |
|
P/E |
? |
|
-80.6 |
264.7 |
25.1 |
25.1 |
-16.9 |
|
63.1 |
P/FCF |
|
|
-96.6 |
25.2 |
17.7 |
17.7 |
71.6 |
|
27.1 |
P/S |
? |
|
3.07 |
2.24 |
1.55 |
1.55 |
1.55 |
|
1.45 |
P/BV |
? |
|
7.40 |
5.19 |
5.75 |
5.75 |
5.21 |
|
4.62 |
EV/EBITDA |
? |
|
-1 165 |
195.1 |
11.6 |
18.3 |
21.9 |
|
11.4 |
Debt/EBITDA |
|
|
-68.7 |
7.75 |
1.24 |
1.96 |
2.28 |
|
1.17 |
|
R&D/CAPEX, % |
|
|
172.8% |
153.8% |
158.5% |
158.5% |
152.8% |
|
144.4% |
|
CAPEX/Revenue, % |
|
|
2.83% |
2.82% |
2.35% |
2.35% |
2.64% |
|
2.77% |
|
Avanos Medical shareholders |